Advanced Filters
noise

carcinoma Clinical Trials

A listing of carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 6,070 clinical trials
C Christy Lee

A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck

This phase II study is a randomized, double-blind study that seeks to evaluate the clinical effects and safety of fucoidan in the treatment of cancer patients with stage III/IV head and neck squamous cell carcinoma. Patients will be centrally randomized in a 1:1 ratio to receive either Fucoidan or placebo …

20 - 75 years of age All Phase 2
H Hai-Qiang Mai, MD,PhD

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

This randomized clinical trial determining whether Sintilimab plus Capecitabine versus Capecitabine alone can improve the progression-free survival rate of NPC patients with unfavorable response to induction chemotherapy. Patients whose plasma EBV DNA> 0 copy/mL or SD/PD according to RECIST1.1 after two cycles induction chemotherapy will have concurrent chemoradiotherapy. MRI, CT …

18 - 70 years of age All Phase 2
S Shiran Sun, Dr.

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

To estimate the efficacy and safety of tislelizumab for stage IVA locally advanced nasopharyngeal carcinoma combined with induction chemotherapy and concurrent chemoradiotherapy, followed by maintenance therapy

18 - 70 years of age All Phase 2
L Liantao Li, M.D., Ph.D.

EBV CAR-T Cells for Nasopharyngeal Carcinoma

The aim of this study is to investigate the safety and preliminary efficacy of EBV CAR-T cells in the treatment of relapsed/refractory NPC

18 - 75 years of age All Phase N/A
R Rahul Ladwa, MD

Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma (cSCC) is typically associated with a high tumour mutation burden, with the majority caused by Ultraviolet (UV) exposure (Pickering et al., 2014). The use of this trial using neoadjuvant Pembrolizumab in patients with cSCC who will otherwise undergo highly morbid radical surgical resection has multiple potential …

18 years of age All Phase 2
D Devarati Mitra

Hypofractionated Radiation Therapy for Merkel Cell Carcinoma

This phase II trial tests whether hypofractionated radiation works to treat patients with Merkel cell carcinoma. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a fewer number of days than tradition radiation therapy courses for …

18 years of age All Phase 2
V Victor Ho-Fun Lee, MBBS

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Hepatocellular carcinoma is one of the most intractable primary malignancies in the hepatobiliary and pancreatic tract with a poor overall survival worldwide. Unfortunately, the vast majority of hepatocellular carcinoma patients suffer from advanced unresectable or metastatic disease at diagnosis. Currently targeted therapy alone, or in combination with anti-vascular endothelial growth …

18 years of age All Phase 2
S Sumati V. Gupta

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

This phase I trial studies the side effects and best dose of belinostat when given together with durvalumab in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and has spread to nearby tissue or lymph nodes …

18 years of age All Phase 1
Z Zhong-Guo liang, PhD

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy alone in treating patients with locoregionally recurrent nasopharyngeal carcinoma.

18 - 65 years of age All Phase 3
X Xiaozhong Chen, MD

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

- 70 years of age All Phase N/A

Simplify language using AI